Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 320.74 Delayed Data As of Jun 23 |  +0.63 / +0.20%Today’s Change | 240.30 Today|||52-Week Range 323.45 | +20.86% Year-to-Date |
The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of NASDAQ ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
| How President Trump Has Sent Biotech Stocks Soaring Jun 23 / TheStreet.com - Paid Partner Content | Healthcare Leads as Stocks Turn Higher After Release of Senate Bill Jun 22 / TheStreet.com - Paid Partner Content |
| Trader's Daily Notebook: Price Momentum Needs to Stick Around Jun 23 / TheStreet.com - Paid Partner Content | Stock Futures Dip as Crude Oil Looks to Correct Days-Long Slide Jun 22 / TheStreet.com - Paid Partner Content |
| 5 Reasons Why Biotech ETFs are Soaring Jun 22 / Zacks.com - Paid Partner Content | The Market Advance Narrows Jun 22 / TheStreet.com - Paid Partner Content |
| 1 month | +10.23% | 3 years | +8.41% | |
| 3 months | +11.13% | 5 years | +20.23% | |
| 1 year | +22.56% | Since inception | +7.52% |
| Previous close | $320.11 |
| Open day’s range | 316.12 – 321.27 |
| Net asset value (NAV) | 320.61 (06/23/2017) |
| Daily volume | 2,623,558 |
| Average volume (3 months) | 1,146,803 |
| IBB | Category | |
|---|---|---|
| Performance 5-yr return | +20.23% | +16.30% |
| Expense Gross exp ratio | 0.47% | 1.33% |
| Risk 5 year sharpe ratio | 0.86 | 1.14 |
| Net assets | $7.7B | $2.9B |
| Average market cap | $16.4B | $28.9B |
| Average P/E | 20.9 | 22.4 |
| Dividend / Share | -- | 0.28% |
| XLV Health Care Select Sector SPDR® Fund |
| FHLC Fidelity® MSCI Health Care Index ETF |
| RYH Guggenheim S&P 500® Equal Weight Health... |
| Healthcare | 99.91% |
| Business service | 0.09% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| REGN Regeneron Pharmaceuticals | 7.97% |
| CELG Celgene | 7.66% |
| GILD Gilead Sciences | 7.61% |
| AMGN Amgen | 7.27% |
| BIIB Biogen | 7.10% |
| VRTX Vertex Pharmaceuticals Inc | 5.20% |
| ILMN Illumina Inc | 4.38% |
| INCY Incyte Corp | 4.02% |
| MYL Mylan NV | 3.53% |
| ALXN Alexion Pharmaceuticals Inc | 3.09% |
